Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys
Rhea-AI Filing Summary
Edesa Biotech, Inc.’s Chief Executive Officer Pardeep Nijhawan reported multiple recent transactions in the company’s common shares. He received a grant of 10,016 restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan, at a stated price of $0.00 per share.
He also bought 20,571 common shares in open-market transactions at a weighted average price of $1.5789 per share and 30,000 common shares at a weighted average price of $2.2232 per share, including purchases held through Pardeep Nijhawan Medicine Professional Corporation. Additional share holdings are reported indirectly through The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Shares | 10,016 | $0.00 | -- |
| Purchase | Common Shares | 30,000 | $2.2232 | $67K |
| Purchase | Common Shares | 20,571 | $1.5789 | $32K |
| holding | Common Shares | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
Footnotes (1)
- The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.2295 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
